Report Overview

UKs Melanoma market size stood at around USD XX.X billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of around xx% during the forecast period.

Although melanoma is still more common in adults older than 65 years, the rates for patients aged 25 to 49 years have increased by 70% since the 1990s, according to the press release. The awareness of melanoma is increasing, and more people are being diagnosed and treated. Melanoma is the second most common cancer in those aged 25 to 49 years and the fifth most common cancer in the U.K. Nearly 90% of melanoma cases could be prevented if people took more initiative to take care of their skin while in the sun. A sunburn just once every 2 years can triple the risk for melanoma, according to the release.



Market Drivers

The prevalence of skin allergies, melanoma, and other skin cancers in developed countries is high, which serves as an opportunity for drug companies to gain a larger share in these regions. Increasing demand for cost-efficient therapeutics in developed regions has encouraged major players to develop cheaper and effective drugs. These factors are expected to fuel the growth of the overall market in the coming years. An increase in melanoma cases, presence of effective immunotherapies acts as primary market drivers for UK melanoma market. Furthermore, Government initiatives aided for that growth, and Technological advancements & increasing R&D on cancer diagnosis and management fuelled the market.